Week 5: Lipid Pharmacology Flashcards

1
Q

Statin Drugs MOA

A

Competitively Inhibits HMG CoA Reductase

So inhibits the conversion of HMG-CoA to Mevalonate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is statin intolerance?

A

The characteristic feature is muscle pain

Think it has something to do with the by-products of cholesterol synthesis (specifically geranyl pyrophosphate and farnesyl pyrophosphate)

As with most drugs, there are other consequences besides the intended therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How does a competitive inhibitor work

A

resembles the substrate of the target molecule but contains a chemical group is added that alters the enzyme’s structure enough to inhibit their activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do competitive inhibitors affect the kinetics

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Does the Km ever change

A

The Km is inherent to the enzyme, however, if for example a competitive inhibitor were added the Km does change but it called the apparent Km

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Km?

A

Concentration of drug @ 50% maximum velocity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe how a Lineweaver-Burke

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Statin effects on HMG CoA levels

A

↓cholesterol

with decreased INSIG dissociated from SCAT and translocates to the Golgi and get cleavage of SREBP and get transcription factor and activates SREBP transcription factor activity

which increases LDL receptor and HMG CoA reductase expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What effect does statin effects on increased LDL receptors have?

A

We are taking it out of the blood which is good for the liver because it can synthesize bile which can dispose of cholesterol

However, Statins it also increases LDL receptor levels in all cell and other cells don’t have a way to get rid of cholesterol so it can exacerbate cholesterolemia problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When is cholesterol synthesis maximized?

A

12 AM - 2 AM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ADME AKA

A

Absorption

Distribution

Metabolism

Excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Statins metaboolized by

A

CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe ADME of statins

A

?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Overview of HMG CoA reductase inhibitors

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Key adverse effects of HMG CoA reductase inhibitors

A
  • Rhabdomyolysis
  • Myoglobinemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the typical dose timing of Statins

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe Liver detoxification systems

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Contraindicated with statin therapy

A

Drugs that use CYP3A4

Also Grapefruit

19
Q

Ezetimibe MOA

A

(dietary cholesterol uptake inhibitor)

NPC1L1 receptor

20
Q

NPC1L1 receptor AKA

A
  • Nieman-Pick C1-Like 1 receptor
  • dietary cholesterol receptor
21
Q

Nieman Picks disease

A

Mutation of NPC1 which is a sphingolipid transporter which is a key component of myelin so usually die young…. learn more about this

22
Q

What is the most common detoxifying enzyme?

A

CYP3A4 detoxifies 90% of drugs

23
Q

Ways to make drugs more hydrophilic to excrete them (Phase 2)

A
  • Bile salt synthesis
  • bilirubin conjugation (glucuronic acid) di-glucuronide bilirubin conjugate
    *
24
Q

Issue with drinking grapefruit juice and many drugs including?

A

Statins

other drugs that use CYP3A4

25
Q

Cholestyramine MOA

A
  • Is a bile acid resin and binds bile acids and inhibits the reabsorption of bile acids in the terminal ileum
  • This causes bile to be synthesized using up cholesterol
  • Net effect is ↓ LDL Cholesterol
26
Q

Where are bile acids typically absorbed?

A

In the terminal ileum

27
Q

Niacin MOA

A
28
Q

Rate limiting step of bile acid synthesis enzyme

A

7α hydroxylase

29
Q

Bile synthesis regulation

A

if there is a lot of bile then it will inhibit 7α hydroxylase

If bile is being excreted 7α hydroxylase will be activated to synthesize more

30
Q

Niacin AKA

A
  • Nicotinic acid
  • Vitamin B3
31
Q

Niacin MOA

A

binds to heterotrimeric G protein Gαi on adipocytes

Gαi inhibits FA release from adipocytes by inhibiting adenylate cyclase

Also inhibits triglyceride synthesis from free FAs in the liver

net effect is preventing efflux of FAs by adipocytes leading to reduced VLDL formation

keeps lipids in fat cells

32
Q

What stimulates FA release from adipocytes

A

heterotrimeric G protein Gαs

33
Q

Niacin ideal for

A

Hypertriglyceridemia

34
Q

Problems with niacin treatment

A

weight loss is difficult because blocking FA efflux from adipocytes

Causes flushing by increasing prostaglandin synthesis in endothelial cells which can have an effect on vasal tone and decrease it and increase flow to the periphery causing flushing

35
Q

List of fibrates

A

Fenofibrate

gemfibrozil

clofibrate

benzafibrate

36
Q

Fibrates MOA

A
  • Binds PPAR-α which is a transcription factor for metabolism which translocates to the nucleus and binds with RXR (retinoic Acid X Receptor)
  • RXR is a cotranscription factor that help with gene expression
  • PPAR-α increases oxidative reactions (primarily in the liver but also in skeletal muscle) Really increases β-oxidation to help reduce hyperlipidemia
  • Net effect is increase β-oxidation to reduce hypertriglyceridemia
37
Q

PPAR-γ target of

A

antidiabetic drugs, more in endocrine

38
Q

PPAR AKA

A

Peroxisome Proliferator Activated Receptor

39
Q

What is PPAR?

A

referred to as master transcription factors of metabolism

40
Q

PCSK9 Inhibitor MOA

A
  • Normally PCSK9 binds to LDL receptor causing the degradation of LDL receptor after it binds to LDL
  • Monoclonal Antibody inhibition of PCSK9 removes it from the LDL receptor and increases LDL receptor expression to clear more LDL from the blood, so now the LDL receptors aren’t degraded and they can take up LDL-C and then return to the surface
41
Q

List of PCSK9 Inhibitors

A

Alirocumab

42
Q

What usually happens when LDL receptor is down-regulated?

A

LDL levels go up

43
Q

What are some ways to downregulate the LDL receptor

A

PCSK9 inhibitors

more

44
Q

How do monoclonal antibodies not cause a severe immune response

A

Monoclonal antibodies are humanized by taking the FC region and replacing it with human sequences reducing the immunoreactivity